A newly identified compound activating UCP1 inhibits obesity and its related metabolic disorders.

Ken OnoderaYutaka HasegawaNozomi YokotaShukuko TamuraHirofumi KinnoIwao TakahashiHiraku ChibaHirotatsu KojimaHideki KatagiriKoji NataYasushi Ishigaki

Published in: Obesity (Silver Spring, Md.) (2023)

The identified compound can serve as a potential therapeutic drug for the treatment of obesity and its related metabolic disorders. Furthermore, our newly clarified thermogenic genes play an important role in UCP1-dependent thermogenesis in adipocytes.

Keyphrases

insulin resistance
adipose tissue
high fat diet induced
metabolic syndrome
weight loss
type diabetes
weight gain
genome wide
emergency department
skeletal muscle
gene expression
dna methylation